Drug EG-301 for dry macular degeneration with patchy vision loss
Part of Eyes & vision clinical trials.
This Phase 2 study tests whether EG-301 is safe and effective for people with a specific type of dry age-related macular degeneration that affects the “geographic atrophy” area. If you have stable eye imaging features and recent worsening vision, you may be able to join and help find a better treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 50 to 75 years old and can attend screening and study visits
- You can sign informed consent and agree to follow the study rules
- You have dry (non-wet) AMD with geographic atrophy in one study eye and it fits specific eye scan measurements
- Your vision has gotten worse over the last 12 months, not from another eye problem
- Your vision in the study eye is within a specific range (about 20/25 to 20/200)
- Your central retina area must look well preserved on eye scans (no signs of the wet form)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a daily eye drop (GAL-101) to see if it can slow the growth of geographic atrophy lesions in people with dry age-related macular degeneration (AMD) when the center of the macula is not yet involved.
This trial tests a new treatment called Eyecyte-RPE™, made from special cells that support the retina. It is given as a single injection under the retina during eye surgery. The study aims to see if it can help people with advanced dry age-related macular degeneration (AMD) who have large areas of damage (geographic atrophy) in the center of their vision.
This trial tests an experimental gene therapy, OCU410, for people with geographic atrophy, an advanced form of dry AMD that causes blind spots in the center of vision. The study aims to see if this treatment can slow down the progression of the disease and help preserve remaining vision.
This trial tests a new medicine called EB-203 for people with wet age-related macular degeneration (AMD), a condition that causes blurry vision. It aims to see if the treatment is safe and can help improve or stabilize vision.
This trial tests a new gene therapy, BS01, given as an eye injection. It is for people with advanced dry age-related macular degeneration (AMD) that has caused geographic atrophy—damage to the central part of the retina. The study aims to see if the treatment is safe and can help slow vision loss.
This study tests an investigational medicine called ONL1204 given as an injection into the eye for people with a form of advanced dry age-related macular degeneration called geographic atrophy. The goal is to see if it can slow vision loss.
Hear when a new Non-Exudative (Dry) Age-related Macular Degeneration (dAMD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.